I appreciate the replies. I find everyone has opinions

New Post Public Reply Private Reply Replies (0) Message Board
Mauibound
378
I appreciate the replies.

I find everyone has opinions and of course it's their right to have them.

I always like to try ( try is the operative word or attempt)
to get an understand where one is coming from because I may have been missing something or was totally unaware of many things.

From your replies, I gather you are super excited to have her on board both Todos & 3CL Pharma.
And you say Todos is lucky to have landed her.

And as you put it. She is "the" gem at Todos.

So, a few things, I'd agree she's badass and I am personally very happy she joined Todos and 3CL Pharma.
I would disagree agree wholeheartedly that she is "the" gem, one of the gems sure, I'll even agree to that.

You're here for the science as you say. And cancer is of interest to you as well, but you haven't mentioned Todos' cancer diagnostics. Videssa™, TM - B2, B1 & C1 or even
LymPro™ .
Granted the only commercial stage dx at present is Videssa™ .

Not nitpicking, just curious why you didn't answer any of the questions I asked.

And again, 100% understand personal opinions, but like I said, I'd like to understand more and that's why I asked.

Which personal patents does she have?
Either. You're not sure, you know and don't want to tell me or share or you don't know.

Do you think her patents as you put it that are held personally have more value than the 3CL ones?
And any thoughts on the additional assets?

Including:
"Additionally, the assets include new intellectual property that covers follow-on products based on Tollovir, including new chemical entity (NCE) therapeutic candidates."
https://investor.todosmedical.com/news-events...assets-and

Last question I have for you is, are you concerned with the amount of hours she's working? I mean how will she divide her time between Todos and 3CL Pharma?
Will that give her any time to work on her personal patents?

You answered-
"Yes, I do think some of her personal patents could be very lucrative. "

I have more questions now, why do you say she's being "locked up"?
I imagine now that Gerald landed the deal that she will be speaking more publicly. But that will be seen.
She was in a delicate situation and couldn't speak much on 3CL Pharma or even what her role was going to be at Todos prior to the deal closing.

I could see Gerald as CEO being blamed 100 % and at fault for not closing the deal, but it's all Dr. Arad doing that the deal did close?


Then in you follow up you are saying she's now not the gem but Dr. Leon is just a Gem worthy?
So, todos has 2 Gems ?
Personally I say yes, he is an absolute Gem to the company as well.

I imagine Dr. Arad getting a seat on the board of at least one of the companies will happen as well

I would add another Gem, Lauren Chung.

I think altogether the science and talent Todos has it makes it a powerhouse of a company.
Now with 3CL Pharma it just adds octane to the valuation which has been reassessed.

"Some markets did. The stock market didn’t. We continue to execute and at some point stock market will catch up to benefit of early investors."
https://twitter.com/G_Commish/status/15049246...A&s=19

In answer to
"@G_Commish are surprised the market didn't revaluate Todos after phase 2 read out?"

It will be interesting to see how 3CL Pharma plays out.
Sold?
Partnered?
Or bought & brought fully under Todos.

I am glad Dr. Arad is stocked to be a part of Todos' team.
She will be a valuable asset.


Todos Med Ltd. (TOMDF) Stock Research Links

TOMDF Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 212

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 245

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 375

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 213

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 238

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 262

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 377

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 301

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 192

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 417

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

APT Miner Mobile App Revolutionizes Cloud Mining Experience

Updated Category News Views 352

APT Miner Mobile App: A New Era in Cryptocurrency Mining APT Miner has launched a groundbreaking mobile application that opens the door to easy cryptocurrency mining for everyone. With this new app, users can seamlessly engage in mining operations from their mobile devices, without the need for technical expertise or complicated setups. The platform caters to a wide range...

Continue Reading
Investors Urged to Act Before September Deadline in Alto Case

Updated Category News Views 233

Important Announcement for Alto Neuroscience Investors In a recent advisory, investors of Alto Neuroscience, Inc. (NYSE: ANRO) are being urged to secure legal counsel as the deadline for a pivotal class action lawsuit approaches. The deadline for lead plaintiffs to step forward is September 19, 2025, providing investors who are affected by a range of factors related to...

Continue Reading
Strategic Sale: McStarlite Co. Partners with Standex International

Updated Category News Views 244

Strategic Changes Ahead for McStarlite Co. In a significant move, Janes Capital Partners has announced its role as the exclusive advisor for McStarlite Co. in its acquisition by Standex International Corporation (NYSE:SXI). This partnership highlights Janes Capital Partners’ capability to navigate complex transactions in the aerospace sector. McStarlite Co.: A Leader in...

Continue Reading
Codis Accelerates Growth with 1315 Capital Investment

Updated Category News Views 185

Codis Secures Funding for Expansion Codis, a leading contract development and manufacturing organization (CDMO) specializing in spray drying and related technologies, is excited to announce a significant growth investment from 1315 Capital. This partnership aims to bolster Codis's manufacturing capabilities significantly, particularly at its Haverhill facility in the UK....

Continue Reading
A Decade of Growth: The Journey of an Investment in Guidewire

Updated Category News Views 174

The Growth Journey of Guidewire Software Guidewire Software (GWRE) has seen significant advancements in the last decade, marking an impressive annualized return of 17.03%. Over this period, it has outperformed the broader market by 4.38%, which speaks volumes about the company’s stability and growth potential. Understanding Guidewire’s Market Position With a current...

Continue Reading